Clinipol Holdings Ltd 09230340 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of a holding company. Digita Accounts Production Advanced 6.30.9574.0 true false 09230340 2024-04-01 2025-03-31 09230340 2025-03-31 09230340 bus:OrdinaryShareClass1 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:OrdinaryShareClass2 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:OrdinaryShareClass3 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:OrdinaryShareClass4 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:OrdinaryShareClass5 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:OtherShareClass1 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:OtherShareClass2 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:OtherShareClass3 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:OtherShareClass4 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 bus:PreferenceShareClass1 bus:CumulativeNon-redeemableShares 2025-03-31 09230340 core:CurrentFinancialInstruments 2025-03-31 09230340 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 09230340 core:CostValuation 2025-03-31 09230340 bus:SmallEntities 2024-04-01 2025-03-31 09230340 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 09230340 bus:FilletedAccounts 2024-04-01 2025-03-31 09230340 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 09230340 bus:RegisteredOffice 2024-04-01 2025-03-31 09230340 bus:Director1 2024-04-01 2025-03-31 09230340 bus:Director2 2024-04-01 2025-03-31 09230340 bus:Director3 2024-04-01 2025-03-31 09230340 bus:Director4 2024-04-01 2025-03-31 09230340 bus:Director5 2024-04-01 2025-03-31 09230340 bus:OrdinaryShareClass1 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:OrdinaryShareClass2 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:OrdinaryShareClass3 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:OrdinaryShareClass4 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:OrdinaryShareClass5 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:OtherShareClass1 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:OtherShareClass2 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:OtherShareClass3 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:OtherShareClass4 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:PreferenceShareClass1 bus:CumulativeNon-redeemableShares 2024-04-01 2025-03-31 09230340 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 09230340 bus:Agent1 2024-04-01 2025-03-31 09230340 countries:EnglandWales 2024-04-01 2025-03-31 09230340 core:CostValuation 2024-03-31 09230340 2023-04-01 2024-03-31 09230340 2024-03-31 09230340 bus:OrdinaryShareClass1 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:OrdinaryShareClass2 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:OrdinaryShareClass3 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:OrdinaryShareClass4 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:OrdinaryShareClass5 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:OtherShareClass1 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:OtherShareClass2 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:OtherShareClass3 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:OtherShareClass4 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 bus:PreferenceShareClass1 bus:CumulativeNon-redeemableShares 2024-03-31 09230340 core:CurrentFinancialInstruments 2024-03-31 09230340 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 09230340

Clinipol Holdings Ltd
Unaudited Filleted Financial Statements
for the Year Ended 31 March 2025

Clinipol Holdings Ltd

Contents

Company Information | 1
Balance Sheet | 2 to 3
Notes to the Unaudited Financial Statements | 4 to 7

Clinipol Holdings Ltd

Company Information

Directors | M. Lord A. P. Hooley A. Holmes D. M. McClellan G. Shaw

Registered office | Unit 3 Garden Court Gee Road Whitwick Business Park Coalville Leicestershire LE67 4NB

Accountants | Robert Whowell & Partners LLP Chartered AccountantsWestwood House 78 Loughborough Road Quorn Loughborough Leicestershire LE12 8DX

Clinipol Holdings Ltd

(Registration number: 09230340)
Balance Sheet as at 31 March 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Investments | 4 | 2,199,101 | 2,199,101
Current assets |  |  |
Debtors | 5 | 667,949 | 292,694
Cash at bank and in hand |  | 258,781 | 31,530
|  | 926,730 | 324,224
Creditors: Amounts falling due within one year | 6 | (355,493) | (175,025)
Net current assets |  | 571,237 | 149,199
Net assets |  | 2,770,338 | 2,348,300
Capital and reserves |  |  |
Called up share capital | 7 | 604 | 600
Share premium reserve |  | 1,200 | 1,200
Retained earnings |  | 2,768,534 | 2,346,500
Shareholders' funds |  | 2,770,338 | 2,348,300

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Clinipol Holdings Ltd

(Registration number: 09230340)
Balance Sheet as at 31 March 2025

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 2 December 2025 and signed on its behalf by:

......................................... A. Holmes Director

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Unit 3 Garden Court
Gee Road
Whitwick Business Park
Coalville
Leicestershire
LE67 4NB

These financial statements were authorised for issue by the Board on 2 December 2025.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in the profit and loss account. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends and other distributions

Dividend and other distributions to the company’s shareholders are recognised as a liability in the financial statements in the reporting period in which the dividends and other distributions are declared.

Share based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 5 (2024 - 5).

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4 | Investments

| 2025 £ | 2024 £
Investments in subsidiaries | 2,199,101 | 2,199,101

Subsidiaries | £
Cost or valuation
At 1 April 2024 | 2,199,101
At 31 March 2025 | 2,199,101
Carrying amount
At 31 March 2025 | 2,199,101
At 31 March 2024 | 2,199,101

5 | Debtors

Current | 2025 £ | 2024 £
Amounts owed by group undertakings | 667,949 | 290,894
Other debtors | - | 1,800
| 667,949 | 292,694

6 | Creditors

Creditors: amounts falling due within one year

| 2025 £ | 2024 £
Due within one year |  |
Amounts owed to group undertakings | 355,493 | 175,025

Clinipol Holdings Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

7 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary share of £1 each | 330 | 330 | - | -
Ordinary A shares of £1 each | 270 | 270 | 306 | 306
Ordinary B shares of £1 each | - | - | 60 | 60
Ordinary C shares of £1 each | - | - | 18 | 18
Ordinary D shares of £1 each | - | - | 12 | 12
Ordinary E shares of £1 each | - | - | 24 | 24
Founder A shares of £1 each | - | - | 60 | 60
Founder B shares of £1 each | - | - | 60 | 60
Founder C shares of £1 each | - | - | 60 | 60
Preference shares of £1 each | 4 | 4 | - | -
| 604 | 604 | 600 | 600